8月7日，A股市场放量上涨，三大指数集体收高。[1][2]上证指数报3940点，涨幅1.02%；深证成指报14311点，涨幅1.42%；创业板指报3563点，涨幅1.35%。[2]科创综指表现更为突出，涨幅达3.35%。[1]全市超2800只个股上涨，[1]沪深两市成交总额约2.68万亿元。[1]
医药板块领涨市场，医疗服务板块上涨8.19%，化学制药板块上涨4.38%。[2]医药相关股票多只涨停，其中贝达药业、百济神州、前沿生物、首药控股、纳微科技等股价均涨逾10%。[2]兴业证券分析师指出，中国创新药全球竞争力持续增强，医药板块正从估值驱动转向业绩和全球化兑现驱动。[2]截至8月3日，A股共有104家医药生物企业发布2026年半年度业绩预告，其中67家公司实现净利润同比增长，占比超六成，28家公司净利润同比增幅超100%。[2]
在医药板块爆发的同时，CPO概念、生物科技、电子元器件、半导体等板块涨幅也位居前列。[1]农业、电信、工程机械、软件、航空、银行等行业则出现下跌。[1]
China's A-stock market posted broad-based gains on August 7, 2026, with major indices rallying across the board. The Shanghai Composite Index rose 1.02%[1], the Shenzhen Component Index climbed 1.42%[1], and the ChiNext Index gained 1.35%[1], while the Sci-Tech Innovation Board Index surged 3.35%[1]. More than 2,800 individual stocks closed in positive territory[1], with total trading volume reaching 2.68 trillion yuan[1].
The pharmaceutical sector led the market advance, with multiple stocks hitting daily limits[1]. The medical services segment surged 8.19%, while the chemical pharmaceutical subsector rose 4.38%[2]. Among notable gainers, Beihua Pharmaceutical, Beigene, Frontier Biotechnology, Firstep Pharma, and Nanosphere Technology all climbed more than 10%[2]. According to Xingye Securities analysts, China's innovative drug competitiveness in the global market continues to strengthen, with the pharmaceutical sector transitioning from valuation-driven gains toward performance and global market realization[2]. As of August 3, a total of 104 pharmaceutical and biotech firms listed on A-stock exchanges released first-half 2026 earnings guidance, with 67 companies achieving year-on-year net profit growth—accounting for over 60% of the group—and 28 of those companies recording profit gains exceeding 100%[2]. Other strong-performing sectors included CPO concept stocks, biotechnology, electronic components, and semiconductors[1].